| 中文名称 |
Baohuoside I
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 中文别名 |
宝藿苷Ⅰ;宝藿苷I;宝霍苷I;宝藿苷 I(P);宝藿苷I 植物提取物,标准品,对照品;脱水淫羊藿素;脱水淫羊藿素 植物提取物,标准品,对照品;淫羊藿次苷;淫羊藿次苷Ⅱ;淫羊藿次苷II;淫羊藿次苷II对照品;宝藿苷I 标准品;脱水淫羊藿苷;宝藿苷I(标准品);宝藿苷I,淫羊藿次苷Ⅱ;宝藿苷Ⅰ(分析标准品);宝藿苷I, 来源于淫羊藿;淫羊藿次苷II 、宝藿苷Ⅰ;淫羊藿次苷II,脱水淫羊藿苷;淫羊藿次苷2;宝藿苷I; 淫羊藿次苷II;宝藿苷 I;宝藿苷I/ 淫羊藿次苷2
|
||||||||||||
| 英文名称 |
Baohuoside I
|
||||||||||||
| 英文别名 |
baohuoside I;3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside;4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-;5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranosideohuside I;Icariin II;Icariside II;5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one;IcarisidII;2h44;Anhydroicaritin;Baohuoside-I;Icariin-II;Icariside-II;Baohuside I;3-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one;[
"Baohuoside I"
];Icarisid;Baohuoside-1;Baohuoside I(Icariside II);Baohuoside I
Baohuside I;5,7-Dihydroxy-4'-methoxy-8-prenyl-3-(α-L-rhamnopyranosyloxy)flavone;Icarisid II;Baohuoside I Icariside II;Baohuoside I, 98%, from Aceranthus sagittatus S. et Z.;Icarlin II;Baohuoside I;;Icarisid II;;C27H30O10;anhydroicaritin-3-O-alpha-L-rhamnopyranoside;N2538;Y0106
|
||||||||||||
| Cas No. |
113558-15-9
|
||||||||||||
| 分子式 |
C27H30O10
|
||||||||||||
| 分子量 |
514.52
|
||||||||||||
| 包装储存 |
|
||||||||||||
| 详情描述 |
Baohuoside I 是从朝鲜淫羊藿中得到的黄酮类化合物,作为 CXCR4 的抑制剂,能够抑制 CXCR4 的表达,诱导凋亡,具有抗肿瘤活性。
|
| 生物活性 |
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity. |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 性状 |
Solid |
||||||||||||
| IC50 & Target[1][2] |
|
||||||||||||
| 体外研究(In Vitro) |
Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells. Baohuoside I inhibits A549 cell viability, with IC50s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38 signaling cascade. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 μg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC50 of 4.8 μg/mL at 48 h. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
| 体内研究(In Vivo) |
Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
| 运输条件 |
Room temperature or refrigerated transportation. |
||||||||||||
| 储存方式 |
|
||||||||||||
| 结构分类 | |||||||||||||
| 来源 | |||||||||||||
| 参考文献 |
|
| 溶解度数据 |
体外研究:
DMSO : ≥ 32 mg/mL (62.19 mM) * "≥" means soluble, but saturation unknown. 配制储备溶液
*
产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效。 体内研究:
建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*
|
|---|
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料,如有违反,将追究法律责任。
沪ICP备2023012080号 |
沪公网安备31011402010657号
扫码关注公众号